ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results Patients diagnosed with hereditary RC are more prone to ...

The SISAQOL-IMI consortium, co-led by the European Organization for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has published a paper in The Lancet Oncology outlining how ...

This study aims to improve survival modeling in head and neck cancer (HNC) by integrating patient-reported outcomes (PROs) using dimensionality reduction techniques. PROs capture symptom severity ...

Please provide your email address to receive an email when new articles are posted on . Use of an electronic patient-reported outcome-based program did not significantly reduce ED or inpatient visits ...

Access to patient-reported outcome (PRO) data significantly improved providers' consistency in assessing adverse events in patients with cancer, with the greatest improvements observed for ...

Patient-reported outcomes (PROs), which assess symptoms, functional status, and quality of life, had independent prognostic value for overall survival in patients with cancer, according to a ...

The SISAQOL-IMI consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), just announced the publication of its pivotal paper in The ...

A large multinational clinical trial has found that giving healthcare providers access to European Organisation for Research and Treatment of Cancer (EORTC) patient-reported outcome (PRO) data ...

Please provide your email address to receive an email when new articles are posted on . Patient-reported physical function predicts which patients gain greatest survival benefit from daratumumab.

The authors acknowledged that longer follow-up (up to 20 years) may be required to detect a potential survival benefit, ...